Cargando…
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/ https://www.ncbi.nlm.nih.gov/pubmed/36670605 http://dx.doi.org/10.3390/children10010054 |
_version_ | 1784873657999294464 |
---|---|
author | Torres-Canchala, Laura Cleves-Luna, Daniela Arias-Valderrama, Oriana Candelo, Estephania Guerra, María Angelica Pachajoa, Harry Olaya, Manuela |
author_facet | Torres-Canchala, Laura Cleves-Luna, Daniela Arias-Valderrama, Oriana Candelo, Estephania Guerra, María Angelica Pachajoa, Harry Olaya, Manuela |
author_sort | Torres-Canchala, Laura |
collection | PubMed |
description | Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations. |
format | Online Article Text |
id | pubmed-9856545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98565452023-01-21 Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 Torres-Canchala, Laura Cleves-Luna, Daniela Arias-Valderrama, Oriana Candelo, Estephania Guerra, María Angelica Pachajoa, Harry Olaya, Manuela Children (Basel) Review Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations. MDPI 2022-12-26 /pmc/articles/PMC9856545/ /pubmed/36670605 http://dx.doi.org/10.3390/children10010054 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Torres-Canchala, Laura Cleves-Luna, Daniela Arias-Valderrama, Oriana Candelo, Estephania Guerra, María Angelica Pachajoa, Harry Olaya, Manuela Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title | Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title_full | Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title_fullStr | Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title_full_unstemmed | Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title_short | Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 |
title_sort | systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/ https://www.ncbi.nlm.nih.gov/pubmed/36670605 http://dx.doi.org/10.3390/children10010054 |
work_keys_str_mv | AT torrescanchalalaura systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT cleveslunadaniela systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT ariasvalderramaoriana systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT candeloestephania systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT guerramariaangelica systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT pachajoaharry systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 AT olayamanuela systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022 |